Despite promising clinical results, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing substantial opposition from PBMs. Such companies are frequently erecting barriers to reimbursement, including significant price restrictions and prior authorization that hinder user access. Analysts sug… Read More